Latest Administration News

Wellard Limited has formally requested to delist from the ASX following the sale of its final revenue-generating vessel, aiming to reduce costs and return excess cash to shareholders. The move awaits shareholder approval at the upcoming AGM.

EVE Health Group has raised $1.1 million to accelerate the commercial rollout of its innovative pharmaceutical products Dyspro and Libbo, signaling strong investor confidence in its growth strategy.

Netwealth Group Limited has reported a landmark quarter with total Funds Under Administration soaring to $120.8 billion, driven by record first-quarter net flows of $4.1 billion and strategic service expansions.

Queste Communications reports steady investment holdings and a robust cash reserve of over $4 million for the quarter ending September 2025, underpinned by its controlling stake in Orion Equities.

PainChek Limited has achieved a landmark FDA De Novo classification for its PainChek Adult App, positioning it as the first regulated medical device for pain assessment in the US aged care sector and opening a $100 million annual market opportunity.

Neurotech International has secured a key FDA designation for its lead drug NTI164, advancing its potential to treat Rett syndrome with regulatory and financial benefits.

IODM Limited reports a striking 179% revenue surge in its UK Education segment for September 2025, driving a 210% year-to-date increase and prompting an upward revision of first-quarter group cash receipts.

Immuron Limited has taken a significant step forward by submitting an Investigational New Drug application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company aims to start Phase 2 trials in early 2026, addressing a critical unmet need in infectious disease treatment.

Dimerix’s latest PARASOL collaboration analysis reinforces proteinuria as a pivotal endpoint in their Phase 3 FSGS trial, setting the stage for FDA discussions on accelerated approval pathways.

Lindian Resources has successfully completed early development works at its Kangankunde Rare Earths Project in Malawi on time and within budget, setting the stage for mining operations to begin in early 2026. The company has also secured key mining equipment and is progressing with infrastructure and process plant preparations.

Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent, progressing toward a Phase 2 clinical trial with strong collaborations and a recent AU$3.5 million capital raise.

Aumake Limited has launched Bio-Basic Ergothioneine, marking the debut of its innovative capital-light incubation model aimed at scaling premium health brands with minimal upfront investment.